Recordati

Drug manufacturing
#Gedeon Richter #Neuropsychiatric disorders #Recordati #UK

Gedeon Richter UK announces transfer of neuropsychiatry product 

Pharmaceutical company Gedeon Richter UK has received full marketing and distribution rights for neuropsychiatry treatment Reagila (cariprazine).  Reagila was acquired by Gedeon Richter UK from Recordati Pharmaceuticals, with Gedeon Richter picking up the rights for UK promotion of cariprazine. The drug is currently licensed in the UK… Read More

#Business & Investment #News

FDA
#FDA #Neurology #Rare disease #Recordati

FDA grants label expansion for Cushing’s disease treatment

The US Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Isturisa (osilodrostat) for the treatment of endogenous hypercortisolemia.  It is now approved in adults with Cushing’s syndrome for whom surgery is not an option or has not been curative.  … Read More

#News #Regulatory